CRISPR and Genome Editing – News and Features

Nanotechnology drug-delivery companies seeking to partner with pharmaceutical companies face competition from a plethora of available drug-delivery systems.

Progress made toward developing next generation molecular medicines to treat obesity and type 2 diabetes.

Now in its second year, the SCIpharm 2006 conference (May 14-17, EICC, Edinburgh, Scotland) will cover all aspects of modern R&D in a four-track format - Gene to Screen, Screen to Candidate, Candidate to Drug and Where Science Meets Business.

Ichor has granted an option for RheoGene to license Ichor’s TriGrid™ Delivery System to develop proprietary therapeutics.

In this Decision Resources report three RNA-based technologies are described.

This versatile package can carry bits of RNA that stop the cell from expressing one of its own genes.

The collection now carries 65,000 shRNA vector constructs that target 9,500 human genes and 3,400 mouse genes.

Lentigen gains exclusive, world-wide license to multisubstrate kinase gene technology.

Genzyme bought extensive gene therapy assets from US company Avigen in December.

Sangamo will use its ZFP technology to develop cell lines for enhanced protein production.